Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gottlieb Unleashed: Focus on Drug Pricing To Intensify As He Rejoins AEI

Executive Summary

Without constraints of being FDA commissioner, Gottlieb will have podium to push for changes to drug pricing and competition.

You may also be interested in...



Gottlieb Shifts From Regulatory To Reimbursement Focus In One Of First Post-Commissioner Appearances

CAR-T reimbursement is concern for former US FDA commissioner Scott Gottlieb in speech at the National Press Club.

Gottlieb Leaves FDA With Final Thought On What To Do About Cosmetics

Addressing for the last time the House Appropriations subcommittee with FDA oversight, Commissioner Scott Gottlieb shared his vision for sharpening cosmetics oversight in the absence of significant new resources.

Gottlieb Leaves FDA Feeling Good About Generic Approvals, But Concerned About Innovative Competition

In interview with the Pink Sheet, US FDA Commissioner Scott Gottlieb offers a final reflection of his time as commissioner.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134409

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel